Ed Boyle

Dr. Boyle is a Cardiovascular and Thoracic Surgeon in Bend, Oregon whose career spans clinical surgery, cardiovascular research, and medical innovation. He studied medicine at University of Minnesota Medical School, and trained in general surgery and cardiothoracic surgery at the University of Washington.

During his clinical training at the University of Washington, he helped lead the Cardiovascular Vascular Biology research team where he developed basic science and clinical research programs, primarily focusing on the study of tissue injury, coagulation and inflammation. Dr. Boyle has published over 75 manuscripts in peer reviewed medical journals and textbooks. In addition to obtaining NIH funding, he played a lead role in developing research collaborations with Bayer’s Pharmaceutical Division, Genentech, Zymogenetics/Novo Nordisk, Icos Corporation, US Surgical Corporation (now Covidien) and other privately held biotechnology and device companies. His research has been recognized nationally with awards from the American College of Surgeons, the American Heart Association, The Western Thoracic Surgery Association, the Seattle Surgical Society and others.

Dr. Boyle was a founder of Elixis, a healthcare information technology company which was acquired by Data Critical Corporation (NASDAQ: DCCA), now a division of General Electric (NYSE: GE). Dr. Boyle is the founder of MDI, VenX, and Precision Thoracic Corporation, all early stage medical device companies where he is an inventor on a number of medical devices patent applications.